umcgkikker2General description: The University Medical Center in Groningen (UMCG) is the largest academic teaching hospital in the Netherlands. It hosts 10000 employees and teaches 4000 students. Three closely collaborating departments of the UMCG will be involved in TransCard: i) The department of Molecular Genetics, ii) the department of Pediatrics, and iii) the department of Genetics.

Websites: www.umcg.nl

Expertise: The UMCG members have a broad experience in studying lipid and carbohydrate metabolism at both the genetic and metabolic level primarily in mouse models but more recently also in humans. To quantify control of metabolic fluxes the groups use state of the art stable isotope based fluxomics approaches using computational modelling to analyze the results. The groups have considerable expertise in systems genetics techniques and for this purpose lead of mouse clinic to be able to generate transgenic mice.

Facilities: Quantitative metabolomics, fluxomics, mass isotopomer dilution analysis, enzymology, cell culturing, mouse transgenic facility, proteomics/metabolomics facility, computational systems biology tools. Access to the LifeLines cohort for studies on healthy ageing. Direct access to patients with MetS and families with mutations in triglyceride (TG) and HDL genes. Facilities to realize clinical intervention trials.

Other EU Projects: HEPADIP (Hepatic and adipose tissue and functions in the metabolic syndrome – FP6-LIFESCIHEALTH – ECGA 018734); HDLOMICS (Functional Genomics of Inborn and Therapeutic Intervention of High Density Lipoprotein – FP6-LIFESCIHEALTH – ECGA 037631); NUCSYS (Systems biology of nuclear receptors: A nutrigenomics approach to aging-related diseases – FP6 MOBILITY – ECGA 19496); UniCellSys (Eukaryotic unicellular organism biology systems biology of the control of cell growth and proliferation – FP7-HEALTH – ECGA 201142). TransCard PIs are currently involved in RESOLVE (FP7- ECGA 305707), the coordinator is Member of the COST HDL network (BM0904) “From biological understanding to clinical exploitation”.